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A B S T R A C T
Hereditary xerocytosis (HX) is a rare, autosomal dominant congenital hemolytic anemia (CHA) characterized by
erythrocyte dehydration with presentation of various degrees of hemolytic anemia. HX is often misdiagnosed as
hereditary spherocytosis or other CHA. Here we report three cases of suspected HX and one case of HX associated
with β-thalassemia.
Sanger method was used for sequencing cDNA of the PIEZO1 gene. Variants were evaluated for potential
pathogenicity by MutationTaster, PROVEAN, PolyPhen-2 and M-CAP software, and by molecular modeling.
Four diﬀerent variants in the PIEZO1 gene were found, including three substitutions (p.D669H, p.D1566G,
p.T1732M) and one deletion (p.745delQ). In addition, in the patient with the p.T1732M variant we detected a
12-nucleotide deletion in the β-globin gene leading to a deletion of amino acids 62AHGK65. The joint presence
of mutations in two diﬀerent genes connected with erythrocytes markedly aggravated the presentation of the
disease. Bioinformatic analysis and molecular modeling strongly indicated likely deleterious eﬀects of all four
PIEZO1 variants, but co-segregation analysis showed that the p.D1566G substitution is in fact non-pathogenic.
Identiﬁcation of causative mutations should improve the diagnosis and management of HX and provide a new
insight into the molecular basis of this complex red blood cell abnormality.
1. Introduction
Hereditary xerocytosis (HX), also known as dehydrated hereditary
stomatocytosis (DHS), is a rare red blood cell membrane disorder re-
sulting in hemolytic anemia with diverse presentation and iron over-
load. Dominantly inherited missense mutations in the PIEZO1 gene
encoding a large mechanosensitive ion channel, aﬀecting mainly its
highly conserved COOH-terminus, have been identiﬁed in HX patients
[1]. They increase the cation permeability of the membrane, which
leads to erythrocyte dehydration. Red blood cells (RBCs) from HX pa-
tients are characterized by a higher Na+ content and a decreased K+
content relative to healthy RBCs [2]. Besides the PIEZO1 mutations,
also mutations in KCNN4 encoding the Gardos channel have been de-
tected in some HX cases [3,4]. The clinical presentation of hereditary
xerocytosis is markedly heterogeneous, ranging from normal he-
moglobin values to severe anemia, with borderline macrocytosis, in-
creased cell hemoglobin content (MCH) and increased mean corpus-
cular hemoglobin concentration (MCHC) [5]. Another type of RBC
disorder with well-understood genetic and molecular etiology is β-
thalassemia. It is a heterogeneous group of hemoglobin disorders due to
a decreased or absent production of normal β-globin chains. A special
form of β-thalassemia defects, called dominant β-thalassemia, is caused
by point mutations or small insertions or deletions leading to the pro-
duction of highly unstable β-globin, which results in the formation of an
unstable tetrameric α2β2 protein. When such mutations generate a
premature stop codon, the mutated mRNA may undergo degradation
through a surveillance mechanism called nonsense-mediated mRNA
decay (NMD). The NMD is not absolutely eﬃcient and the mRNAs es-
caping degradation give rise to truncated β-globin chains, resulting in
highly variable symptoms among carriers of the same variant. Hetero-
zygotes for a dominant β-thalassemia mutation show typical anemia
symptoms [6], whereas activation of NMD only leads to a mild anemia
or is symptomless. Combined defects of the red cell membrane with
other lesions aﬀecting erythrocytes are very rare and diﬃcult to diag-
nose properly. Only few HX cases associated with a thalassemia or RBC
enzymopathy have been reported [7]. The aim of our study was to
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elucidate the molecular basis of hereditary xerocytosis in four Polish
patients with suspected HX or an undiagnosed congenital hemolytic
anemia. Four previously uncharacterized variants in the PIEZO1 gene
were identiﬁed and, in one patient, a co-existing deletion in the β-
globin gene. Homology modeling was performed in order to predict the
eﬀects of the identiﬁed variants on the structure of PIEZO1 and β-
globin proteins and thereby their likely mechanism of pathogenicity.
Family co-segregation studies were used to verify the predicted pa-
thogenicity of two of the novel variants.
2. Materials and methods
2.1. Case presentation
2.1.1. Patient 1
A 16-year-old girl has been under the care of the outpatient de-
partment of a hematology division since birth due to hemolytic anemia
of unknown etiology. She was hospitalized many times as she required
packed red blood cells transfusions which occurred mainly during in-
fections. Additionally, growth hormone deﬁciency, familial adenoma-
tous polyposis (FAP) and Gilbert Syndrome were diagnosed. Mother
and sister of the proband were asymptomatic. The father of the patient
was unavailable for genetic studies. It is only known from an interview
that he exhibited no symptoms of hemolytic anemia.
2.1.2. Patient 2
An 18-year-old girl with hemolytic anemia of unknown etiology has
been observed since birth. She was hospitalized occasionally for packed
red blood cells transfusions. Initially she was diagnosed with congenital
dyserythropoietic anemia type II. A ﬂow cytometry test with eosin-5′-
maleimide (EMA) staining for red cell membrane disorders showed
lowered ﬂuorescence intensity compared with normal samples. At the
age of 3, splenectomy was performed with no beneﬁcial eﬀect; no
thrombolic event has been reported. Finally, other possible causes of
anemia were excluded and diagnosis of HX was established. Mother,
father and brother of the proband were asymptomatic.
2.1.3. Patient 3
A 59-year-old man complaining of weakness and fatigue since 2012.
Lab studies revealed occasional mild anemia accompanied by elevated
reticulocyte count and mild hyperbilirubinemia. In December 2017 he
had an episode of severe abdominal pain located in the left upper
quadrant of the abdomen. Gallstones were diagnosed and managed
conservatively. Physical examination revealed no abnormalities. No
family members were available for analysis. It is only known from an
interview that the both parents exhibited no symptoms of hemolytic
anemia.
2.1.4. Patient 4
A 3-year-old boy has been under the care of the outpatient depart-
ment of a hematology clinic since birth due to hemolytic anemia of
unknown etiology. Hereditary spherocytosis, enzymopathy of red cells
and autoimmune hemolytic anemia were excluded. Since hemoglobin
analysis showed elevated levels of hemoglobins F and A2, β-thalassemia
was diagnosed. Red cell morphology demonstrated target cells in as-
sociation with stomatocytes and microspherocytes (Fig. 1), and red cells
displayed profoundly decreased osmotic fragility. He still requires
regular and frequent packed red blood cells transfusions. Parents of the
patient 4 refused to donate blood for the purpose of genetic analysis.
The hematological data of the probands are shown in Table 1.
Informed consent has been obtained from the patients or their
parents, as appropriate, and the study protocol approved by the Ethics
Committee of the Medical University of Warsaw.
2.2. DNA isolation
The QIAquick® DNA Blood Mini Kit (Qiagen, Hilden, Germany) was
used to isolate genomic DNA from peripheral blood samples.
2.3. RNA isolation and reverse transcription
Total RNA was isolated from peripheral blood samples using the
PAXgene Blood RNA Kit (QIAGEN, Hilden, Germany). Reverse tran-
scription (RT) was performed using the QuantiTect Reverse
Transcription Kit (QIAGEN, Hilden, Germany) according to the manu-
facturer's recommendations.
2.4. DNA and cDNA sequencing
Genomic DNA was used to amplify the promoter region, entire
coding sequence and ﬂanking sequences of the β-globin gene by PCR.
cDNA template was used for ampliﬁcation of the coding sequence of
the PIEZO1 gene. DNA fragments generated by PCR ampliﬁcation were
puriﬁed using the QIAquick PCR Puriﬁcation Kit (QIAGEN, Hilden,
Germany) and sequenced directly with BigDye Terminators and ap-
propriate primers using an ABI Prism 377 sequencer (Applied
Biosystems, Foster City, CA, USA). The mutations detected in cDNA
were veriﬁed by sequencing of genomic DNA. Detected variants were
evaluated for potential pathogenicity by MutationTaster [8], PROVEAN
[9], PolyPhen-2 [10] and M-CAP software [11].
The sequences of all primers and the annealing temperatures used
for PCR are available upon request.
2.5. Molecular modeling
The structure of the human PIEZO1 ion channel has not yet been
determined experimentally, so it was modeled by homology using the
recently determined cryo-electron microscopy structure of mouse
Piezo1 (pdb6b3r). An initial structure of the protein was modeled using
the SWISS-MODEL server [12], and more precise modeling was then
performed for fragments T561-D710, E811-P960 and A1672-P1813
with the use of Yasara Structure [13] and further tuned with FoldX
[14]. The thermodynamic eﬀects of the D669H and T1732M substitu-
tions were assessed with the use of FoldX.
The low-complexity region comprising the sequence 745QQQQQE-
EEEEEE756 was modeled in the helical form, in agreement with the
secondary structure predictions performed using the APSSP2 [15] and
CFSSP [16] web servers.
Fig. 1. Peripheral blood ﬁlm (PBF) of patient 4 showing target cells (1), sto-
matocytes (2), microspherocytes (3) and leptocytes (4).
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A homology model of β-globin lacking the 62AHGK65 fragment was
obtained using the SWISS-MODEL server [12]. As a template the 3D
structure of human hemoglobin was used (PDB code: 1DXT0) [17].
3. Results
All the probands exhibited variable degrees of anemia with the
presence of stomatocytes in the blood smear, and reticulocytosis.
Sequencing of the PIEZO1 cDNA showed four previously un-
characterized variants, one in each patient (Table 2, Supplemental
Figure 1S).
They were conﬁrmed by sequencing corresponding regions of their
genomic DNA. In patient 1 the c.2005 G > C variant causes a sub-
stitution of aspartic acid with histidine at position 669 (p.D669H). In
this patient symptoms of anemia/jaundice have been noted since birth
and she was occasionally transfused. The most signiﬁcant laboratory
ﬁndings were: hemoglobin (Hb) concentration of 8.1 g/dL and a sig-
niﬁcantly decreased number of red blood cells with slightly elevated
red blood cell distribution width (RDW). Her mother and sister have
never been anemic, and DNA sequencing did not show the presence of
the c.2005 G > C substitution. p.D669H was categorized as a disease-
causing mutation by all the bioinformatics software used. Molecular
modeling showed that the D669H replacement destabilizes the protein
structure only slightly (~0.4 kcal/mol, see Fig. 2). It should be men-
tioned, however, that the loop separating TM14 and TM15 (residues
650–690) carries a stretch of negatively charged residues D651, D664,
E665, D669, E673 and E679, all of which are generally conserved in the
homologous sequences and therefore are expected to be functionally
important. Thus, the D669H substitution, which markedly changes the
charge distribution along this loop could aﬀect intermolecular inter-
actions of PIEZO1 with an unidentiﬁed partner.
Patient 2 carries the c.4697 A > G substitution changing aspartic
acid to glycine at position 1566 (p.D1566G). This variant was also
bioinformatically classiﬁed as disease-causing, but less harmful than
the variant in patient 1. Indeed, patient 2 showed a milder form of
hemolytic anemia than patient 1. Since no reasonable template
Table 1
Hematological parameters of the patients.
Patient Age
[years]/sex
RBC
[106/μL]
Retic
[%]
Ht
[%]
Hb
[g/dL]
MCV
[fL]
RDW
[%]
MCH
[pg]
MCHC
[g/dL]
Ferritin
[ng/mL]
Total billirubin
[mg/dL]
LDH
[U/L]
OF EMA
[%]
HbA2
[%]
HbF
[%]
Normal value – 4.2–5.4 0.6–2.6 37–47 12–16 81–99 11–15 27–31 32–36 4.4–207.0 0.2–1.3 #143–279
⁎470–900
>86 <2.5 < 1
1 16/F 2.41 3.4 22.4 8.1 92.9 17.4 33.6 36.2 637.6 12.0 121# dec 115 nd nd
2 18/F 3.36 1.8 28.3 9.2 84.2 25.2 27.4 32.5 2560.8 1.0 nd dec 79 nd nd
3 59/M 3.51 3.6 nd 12.9 100.6 15.3 nd nd 829.5 1.7 359# nd nd nd nd
4 3/M 2.54 3.2 27.6 7.5 111 28.8 29.4 26.5 12.3 4.2 3400⁎ dec 135 5.5 6.0
RBC - red blood cell, Retic - reticulocyte; Ht - hematocrit; Hb - hemoglobin; MCV - mean corpuscular volume; RDW - red blood cell distribution width; MCH - mean
corpuscular hemoglobin; MCHC - mean corpuscular hemoglobin concentration; LDH - lactate dehydrogenase; OF - osmotic fragility; EMA - the eosin-5′-maleimide
binding test; HbA2 - hemoglobin A2; HbF - hemoglobin F; dec - decreased; nd - not detected.
Table 2
Heterozygous PIEZO1 and β-globin variants identiﬁed in the patients.
Patient Gene Nucleotide variants
(Variant dbSNP)
Amino acid mutations Type Prediction
MutationTaster PROVEAN PolyPhen2 M-CAP
1 PIEZO1 c.2005 G > C p.D669H missense “disease causing” −5.354 1 0.649
2 PIEZO1 c.4697 A > G
(rs759704861)
p.D1566G missense “disease causing” −3.665 0.364 0.750
3 PIEZO1 c.2233_2235delCAG p.745delQ deletion “polymorphism” 0.285 – –
4 PIEZO1 c.5195C > T
(rs139051768)
p.T1732M missense “disease causing” −4.135 1 0.508
4 β-globin c.187_198del12 p.62-65delAHGK deletion “disease causing” −31.814 – –
MutationTaster is a web-based application for evaluation of DNA sequence variants for their disease-causing potential.
PROVEAN predicts whether an amino acid substitution or indel has an impact on the biological function of a protein; scores equal to or below−2.5 are considered
„deleterious”.
PolyPhen2 predicts whether an amino acid substitution or indel has an impact on the biological function of a protein; scores range from 0 (tolerated) to 1 (dele-
terious).
M-CAP is a pathogenicity classiﬁer for rare missense variants in the human genome; scores above 0.025 are considered “deleterious”.
Fig. 2. Structure of T561-P960 fragment of Piezo1. The F649-S676 loop is
stabilized by two salt bridges between D669 and E673, and K601. The D669H
substitution present in Patient 1 destroys a network of interactions, bringing
about destabilization of this loop. Residue 669 is depicted as a balls-and-sticks
model; aspartate present in unmutated protein is shown. Arrow marks its ionic
interaction with K601.
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structures were available for the Q1298-E1677 region of PIEZO1, pre-
dicted as an extramembrane sub-domain, the eﬀect of the D1566G re-
placement could not be studied by homology modeling. It is expected
that the introduction of a glycine residue should destabilize the struc-
ture. Notably, sequencing of family members has revealed that the
variant occurs also in the asymptomatic brother and father of the pa-
tient, indicating that it should be regarded as benign, in contrast to the
bioinformatic predictions.
In patient 3 the c.2233_2235 CAG deletion removes one glutamine
residue from the stretch of glutamines at positions p.745–749. This
deletion was categorized as non–disease-causing, in accordance with
the mild symptoms of compensated anemia presented by this patient. In
spite of these results, molecular modeling showed that the Q deletion
would change the size and consequently the charge distribution on a
putative helical region, which could aﬀect intermolecular interactions
(Supplemental Figure 2S). No family members of the patients were
available for analysis.
Patient 4 carries the c.5195C > T variant which results in the
substitution of threonine with methionine at position 1732
(p.T1732M). Patient 4 presents with macrocytosis, massively decreased
MCH, and increased RDW. This variant was classiﬁed as disease-
causing. Residue 1732 is located at the interface of transmembrane
helices TM27 and TM28. The T1732M substitution was found to sta-
bilize the protein structure markedly, by - 2 kcal/mol. Such excessive
stability could compromise the functioning of PIEZO1. On the other
hand, its paralog Piezo2 in the mouse, pongo and human does contain
methionine in the corresponding position, which argues against a det-
rimental eﬀect of the T1732M variant (Supplemental Figure 3S). We
were unable to perform co-segregation analysis of the patient's family.
Since patient 4 showed elevated levels of HbF and HbA2 and the
presence of target cells in the blood smear, we sequenced his β-globin
gene. A 12-nucleotide in-frame deletion (GCTCATGGCAAG) involving
codons 62–65 in the second exon, leading to a deletion of amino acids
62AHGK65, was found. Our modeling indicates that this deletion causes
a deformation of the heme pocket, particularly on the distal side, likely
aﬀecting oxygen binding (Fig. 3). Moreover, histidine 63 is engaged in
an interaction with the heme moiety at its distal side, and its absence by
itself should compromise the binding of oxygen.
4. Discussion
Hereditary xerocytosis syndromes are the most common disorder of
erythrocyte volume homeostasis and are the most clinically hetero-
geneous [18]. The degree of anemia varies in severity, with an onset in
the fetal period or late in life. Beside chronic anemia and its typical
complications, such as iron overload, no other signs are observed with
the exception of transient perinatal edema and hydrops fetalis [18].
Peripheral blood smear demonstrates stomatocytes - mouth-shaped
erythrocytes. The reticulocyte count is elevated, and red cell mean
corpuscular volume (MCV) and mean corpuscular hemoglobin con-
centration (MCHC) are slightly increased. Splenectomy should not be
performed in the cases of hereditary xerocytosis due to an increased risk
of venous thrombosis [19]. The majority (83%) of HX cases are caused
by missense mutations in the PIEZO1 gene, and rare cases related to the
KCNN4 gene, which encodes the Gardos channel, have also been re-
ported [20].
In the present analysis of four unrelated putative or diagnosed HX
cases with highly diﬀerent presentations we found four diﬀerent var-
iants in the PIEZO1 gene, including three substitutions and one dele-
tion. The p.D669H variant of patient 1 aﬀects the same position as the
causative D669Y mutation described recently [20,21] in three un-
related families. The p.D1566G (patient 2) and p.T1732M (patient 4)
variants, and the p.745delQ deletion (patient 3) are noted in dbSNP and
scored of “unknown signiﬁcance”.
The factors responsible for the strikingly diﬀerent clinical manifes-
tations of HX and its severity are still poorly understood. Some studies
suggest that the clinical features of HX are, at least to some extent,
related to the location of the causative mutation [20]. When non-cri-
tical parts of the PIEZO1 channel are aﬀected, the resulting defect can
vary greatly in strength. Such was the case for our patients 1 and 3
presenting with, respectively, typical strong and mild HX features. In
both of them the mutations located to regions encoding peripheral
helices of PIEZO1, exons 16 and 17, respectively [21].
Patient 4 was unusual as he carried two apparently unrelated mu-
tations aﬀecting the RBC: a missense mutation in the PIEZO1 gene and a
12-nucleotide in-frame deletion in the β-globin gene. Both these mu-
tations were conﬁrmed as pathogenic by diﬀerent algorithms, and
molecular modeling of the T1732M mutated PIEZO1 protein showed its
markedly higher stability compared to the normal variant. At face value
this is not a typical signature of pathogenic mutations. However, one
should bear in mind that protein functioning requires a considerable
degree of conformational ﬂexibility, therefore an excessive structural
stability can actually be detrimental. Notably, de novo-designed pro-
teins often show substantially higher stability than their natural coun-
terparts, which suggests that their conformations (and the underlying
amino acid sequences) shaped by evolution are not the most stable
structures possible but rather represent a trade-oﬀ optimum between
high stability and the ﬂexibility required for functioning. On the other
hand, one should note that a paralog of Piezo1, Piezo2, does contain a
methionine at position corresponding to residue 1732 of Piezo1 in the
mouse, pongo and human, which does not compromise its activity.
Taken together, these informations suggest that the T1732M substitu-
tion in PIEZO1 could aﬀect the erythrocyte stability, albeit only func-
tional studies of this PIEZO1 variant will prove that this is indeed so.
Dominantly inherited β-thalassemias are due to mutations that lead
to production of a truncated or elongated and highly unstable β-globin
chain. Mutations of this type have been found in many diﬀerent ethnic
groups, with very low frequency. Aﬀected individuals have moderate to
severe anemia, splenomegaly and the hematological features of β-tha-
lassemia – elevated HbA2 and imbalanced globin chain synthesis [22].
Combined defects of red cell membrane and metabolism are very rare
and diﬃcult to diagnose properly, and carriership for a metabolic de-
fect can modify the clinical picture of the patient. In fact, reports on the
Fig. 3. Eﬀect of deletion of amino acids 62AHGK65 on β-globin structure. β-
globin structure is shown as gray ribbon. Helix V60-L75, where the deletion is
localized, is shown in blue, with residues 62–65 light blue for the native pro-
tein, and in yellow for the mutant. Heme is shown in red. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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impact of co-occurring mutations responsible for various defects of the
red blood cell are inconclusive. It has been noted that the concomitance
of β-thalassemia and hereditary spherocytosis can in fact reduce the
degree of hemolysis [23]. In contrast, Fermo et al. [7] state that the
hemolytic eﬀect of hereditary spherocytosis associated with pyruvate
kinase deﬁciency and the β-thalassemia trait does not diﬀer from the
typical HX cases. Furthermore, the coexistence of mutations in the er-
ythrocyte membrane protein 4.2 gene and α-thalassemia-causing de-
letions results in a decreased hemoglobin concentration, microcytosis,
and an increased red cell distribution width value [24]. Similarly,
hereditary xerocytosis due to a PIEZO1 mutation combined with the
hemoglobin C (HbC) trait was associated with increased clinical se-
verity [25]. Glogowska et al. [26] presented a patient with a PIEZO1
mutation coinherited with heterozygous β-globin Cincinnati. A patient
with an almost identical β-globin mutation (β-globin Geneva) exhibited
only mild microcytic anemia [27], while in the former case the clinical
severity was more profound and the patient had to be transfused reg-
ularly. In contrast, a deletion aﬀecting codons 63–65 (c.189_195del
TCATGGC) in a family from China leads to the β(0)-thal phenotype, but
one should note that it causes a shift in the reading frame and a pre-
mature stop codon that causes nonsense-mediated decay of the mutant
messenger RNA [28].
The severe clinical symptoms of patient 4 are unlikely to have been
caused by the (previously not reported, therefore uncharacterized) β-
globin defect alone. The deletion of the four amino acid residues 62–65
of β-chain results in a deformation of the heme pocket, particularly its
distal side, indicating a consequent disorder in the oxygen-iron complex
formation. The absence of the distal histidine important for the Fe-O-O
coordination must itself have a similar eﬀect. Whether the clinical
picture of the patient is caused by a strong modifying eﬀect of the
otherwise non-detrimental mutation in PIEZO1, or is combined eﬀect of
two strongly deleterious mutations, cannot be decided at present.
To summarize, four previously clinically uncharacterized mutations
in the PIEZO1 gene have been identiﬁed in as many patients with di-
verse forms of hemolytic anemia. For two of them the predicted clinical
signiﬁcance and molecular modeling consistently pointed to their pa-
thogenicity, while in the other two cases the results were less clear-cut.
Notably, family studies excluded a pathogenic eﬀect of the p.D1566G
variant predicted to be deleterious, therefore for this patient the genetic
basis of the disorder remains to be identiﬁed.
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